Project Grant R44TR006356
Award Date 8/1/26
Completion Date 1/31/27
Dollars Obligated $245K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Del Mar, CA 92014, USA
Similar Awards
- The National Institute on Drug Abuse awarded Boston Medical Center Corporation $2,066,706 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and test systems for integrating pre-exposure prophylaxis (PrEP) prescriptions into hospital inpatient workflows as a HIV prevention strategy for people who use drugs. The award funds PREP-TALK, a project that addresses the gap between the proven efficacy of PrEP and its confinement to outpatient settings, where...
- The National Institutes of Health Office of the Director awarded Fred Hutchinson Cancer Center $1,000,792 on September 12, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to conduct a hybrid effectiveness-implementation cluster-randomized controlled trial testing telehealth-supported delivery of HIV pre- and post-exposure prophylaxis (PrEP and PEP) at private pharmacies in Kenya. The study will randomize 20 pharmacies across Kisumu and Homa Bay Counties in Western Kenya...
- The National Institute on Drug Abuse awarded Public Health Foundation Enterprises, Inc. (doing business as Heluna Health) $1,177,338 on April 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to test and expand the Street Prep intervention, a low-barrier HIV pre-exposure prophylaxis delivery model for people who use drugs and experience homelessness in San Francisco. The project conducts a Type 2 hybrid effectiveness-implementation randomized trial enrolling 150...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $691,288 on July 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the PREP Optimization in Women via Event-Driven Regimens (POWER) study, a pharmacokinetic and pharmacodynamic investigation of emtricitabine/tenofovir disoproxil fumarate (F/TDF) pre-exposure prophylaxis in women receiving exogenous hormone therapy. The study quantifies F/TDF drug...
- The National Institute of Child Health and Human Development awarded The Regents of the University of California, San Francisco $408,643 on February 1, 2026, under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct an implementation science study evaluating pharmacy-based HIV pre-exposure prophylaxis (PrEP) provision and adherence support for adolescent girls and young women in Uganda. The recipient will conduct a mixed-methods study examining...
- The National Institute on Drug Abuse awarded New York University $256,165 on May 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and evaluate PREP-RISE, a multi-level photovoice intervention designed to improve pre-exposure prophylaxis (PrEP) uptake and adherence among women who inject drugs. The intervention addresses barriers to PrEP adoption by integrating targeted education during participatory photovoice sessions, building trust, and facilitating warm...
- The National Institute of Mental Health awarded Public Health Foundation Enterprises, Inc. (doing business as Heluna Health) $659,242 on March 5, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate the PrEP Blueprint, an implementation toolkit designed to help clinics scale up and expand access to multiple types of pre-exposure prophylaxis (PrEP) options. The project unfolds in two phases. In Year 1 (Phase 1, Aim 1), the recipient will conduct...
- The National Institute of Mental Health awarded the University of Pennsylvania $1.488 million on September 18, 2025, under the Mental Health Research Grants program (CFDA 93.242) to develop and evaluate STEP-UP (Streamlining Telehealth for Expanded PrEP Utilization Through Community Partnerships), an implementation-effectiveness pilot study integrating telehealth pre-exposure prophylaxis delivery into community-based organizations serving individuals at elevated risk for HIV acquisition. Over...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $696,200 on May 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct the OPAL Study, a pharmacokinetic and pharmacodynamic investigation of emtricitabine/tenofovir disoproxil fumarate (F/TDF) pre-exposure prophylaxis (PrEP) dosing regimens in women across the lifespan. The award funds research to evaluate whether a 2-2-2 event-driven F/TDF dosing regimen...
- The National Institute on Drug Abuse awarded Duke University $726,750 under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 1, 2026, for development and pilot implementation of a community-partnered digital health platform to enhance HIV pre-exposure prophylaxis (PrEP) linkage and retention among people who use drugs. The project applies human-centered design to develop a tailored digital health platform and implementation protocol for long-acting injectable PrEP delivery...